When is Ozempic typically denied?
Ozempic is Novo Nordisk's semaglutide formulation indicated for adults with type 2 diabetes, and cardiovascular risk reduction in adults with T2D and established CVD. Insurance denials are common — particularly for plans that restrict GLP-1s to specific diagnoses or require step therapy. Knowing the exact denial reason on your Explanation of Benefits (EOB) is the first step toward a successful appeal.
Common denial reasons & how to counter them
Prescribed off-label for weight loss
If the goal is weight management, request a switch to Wegovy (same molecule, on-label for obesity). Plans rarely cover Ozempic without a T2D diagnosis.
Step therapy with metformin required
Submit documentation of metformin trial — dose, duration, A1c response, intolerance, or contraindication.
A1c below plan threshold
Many plans require A1c ≥ 7%. Submit the most recent A1c and document why earlier intervention is medically appropriate (e.g., cardiovascular risk per ADA guidance).
Quantity limit exceeded
If titrating to a higher dose, submit a prior auth quantity-limit exception with clinical justification.
Documentation checklist
Strong appeals are built on documentation. Ask your prescriber's office to include each of the following in the appeal packet:
- T2D diagnosis with ICD-10 code (E11.x)
- Most recent A1c with date and trend over past 6–12 months
- Documented metformin trial (dose, duration, outcome) or contraindication
- Cardiovascular risk factors or established ASCVD diagnosis if applicable
- Current diabetes medication list
- Letter of medical necessity from prescriber
- Copy of the original denial letter / EOB
Sample appeal letter for Ozempic
Copy the letter below into your appeal and have your prescriber personalize the clinical details. Always attach supporting chart notes and lab results.
[Date] [Insurance Plan Name] Attn: Appeals Department [Address] Re: Appeal of Denial — Ozempic (semaglutide injection) Member: [Patient Name] Member ID: [ID] Claim/Reference #: [from denial letter] To the Appeals Reviewer: I am writing to appeal the denial of Ozempic (semaglutide) issued on [denial date]. The stated reason was: "[exact reason from EOB]." [Patient] is a [age]-year-old [sex] with type 2 diabetes mellitus (ICD-10: E11.9), most recent A1c of [value] on [date], despite [list current therapies — e.g., metformin 2000 mg/day, lifestyle modification]. [Patient] also has [relevant cardiovascular risk factors or established ASCVD], which strengthens the indication for a GLP-1 receptor agonist per the ADA Standards of Care. Ozempic is FDA-approved as adjunct to diet and exercise to improve glycemic control in adults with T2D and to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. The ADA recommends GLP-1 receptor agonists as preferred second-line therapy for patients with T2D and ASCVD or high cardiovascular risk. Enclosed please find: chart notes, A1c trend, prior medication trials, and the letter of medical necessity. I respectfully request that this denial be overturned. Sincerely, [Prescriber Name, Credentials] [Practice / NPI]
FAQ
Get a Ozempic approval-likelihood score
Answer a few clinical questions and receive a personalized assessment of your approval odds, plus a prior-authorization checklist tailored to your plan.
Educational guidance only — not medical or legal advice.